[April 21, 2015] |
|
ClinEdge, LLC Announces Collaboration with Sister Company BlueTheory Clinical Trials, LLC
The ClinEdge team is thrilled to unveil its collaboration with sister
company, BlueTheory Clinical Trials. ClinEdge President Christian Burns
and Vice President Alfred Peters are excited to announce BlueTheory as
they feel that the sister company can provide research sites, CROs, and
sponsors with a wider range of services than ever before. In order to
join the ClinEdge network, sites must meet and maintain specific
rigorous criteria. BlueTheory's unique approach allows the company to
work with all types of research sites, from established multispecialty
centers to newer single-specialty sites. BlueTheory is able to match
sites to appropriate trials based on study-specific criteria outlined by
the sponsor or CRO. BlueTheory's detailed study-specific feasibility
analysis ensures BlueTheory sites meet all required qualifications prior
to sponsor introduction. All BlueTheory sites utilize a vast array of
services, including business development, call center access, marketing,
regulatory, and QA support. BlueTheory's experienced financial team can
also help sites with contract and budget negotiations and receivable
tracking.
While working with the smaller ClinEdge Network, Christian found that
ClinEdge would receive many quality study opportunities from sponsors
and CROs that they would not be able to support due to competing studies
or insufficient patient populations. BlueTheory's network of research
sites has provided the opportunity to still assit these sponsors and
CROs in the event that ClinEdge cannot support the demand.
BlueTheory is the first trial management company to customize its
services to the needs of each individual research site. All services can
be implemented on an ongoing or per-study basis. BlueTheory Partner
Sites retain their autonomy while leveraging the strength of a cohesive
network.
BlueTheory collaborates with over 150 multi-specialty research sites.
Scott Palmese, Associate Director of Business Development at BlueTheory,
is excited to discuss the collaboration between ClinEdge and BlueTheory:
"CROs have enjoyed working with us because of the detailed,
study-specific site evaluation process that we utilize before any sites
are introduced for their trials." BlueTheory vets each Partner Site with
study-specific information prior to submission to ensure that only the
best fit sites are presented to CROs and Sponsors. This process is so
effective that out of the 8 facilities introduced by BlueTheory for a
recent osteoarthritis study, all 8 were selected by the CRO as top
candidates.
ClinEdge and BlueTheory are able to work exceptionally well together
with sponsors and CROs due to the wide variety of research sites within
the two networks. When sponsors and CROs collaborate with both
BlueTheory and ClinEdge, they will have no problem filling their studies
with high-performing clinical research sites. Although ClinEdge and
BlueTheory are sister companies, they are separate entities. Each
company uses its own confidentiality processes and works independently
with sponsors and sites.
About ClinEdge
ClinEdge is a full-service business development, marketing, and patient
recruitment firm dedicated to the success of clinical trials.
Headquartered in the greater Boston area, the company's two divisions,
ClinEdge Engage, a leader in patient recruitment and retention, and
ClinEdge Network, a network of high-performing investigational
facilities across the US, Canada, and Puerto Rico, cultivate and
maintain strong relationships with the world's leading research
facilities, pharmaceutical companies and contract research organizations
(CROs).
About BlueTheory Clinical Trials
BlueTheory Clinical Trials is an organization dedicated to matching
research facilities across the US and Canada with new trial
opportunities. BlueTheory has established relationships with CROs and
pharmaceutical companies around the world in order to bolster the
pipelines of our Partner Sites. Ensuring our Partner Sites are a good
fit based on study-specific criteria and enforcing a shortened document
turnaround time lead to a streamlined site identification process and
quick study start-up.
[ Back To TMCnet.com's Homepage ]
|